NeuBase Therapeutics, Inc. (NBSE)
Chart Events
Performance Outlook
| Previous Close | 0.1798 |
| Open | 0.1808 |
| Bid | 0.1752 x 3000 |
| Ask | 0.1870 x 800 |
| Day's Range | 0.1750 - 0.1880 |
| 52 Week Range | 0.1630 - 1.9900 |
| Volume | |
| Avg. Volume | 341,089 |
| Market Cap | 6.215M |
| Beta (5Y Monthly) | 0.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9310 |
| Earnings Date | May 10, 2023 - May 15, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- GlobeNewswire
NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023
PITTSBURGH, Feb. 14, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the three-month period ended December 31, 2022, and other recent developments. “We plan on leveraging our PATrOL™ platform to perform ‘nuclease free’ in vivo gene editing to restore healthy gene funct
- American City Business Journals
NeuBase Therapeutics selling stake in company to New York investment firm Alumni Capital
NeuBase specializes in genetic medicine therapies that target disease-triggering DNA and RNA mutations.
- GlobeNewswire
NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022
PITTSBURGH, Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the fiscal year ended September 30, 2022, and other recent developments. “Fiscal year 2022 was a challenging period in our Company’s history as we faced a tightening of the broader capital markets for
